Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma
10.1159/000518619
Saved in:
Main Authors: | Ng K.Y.Y., Tan S.H., Tan J.J.E., Tay D.S.H., Lee A.W.X., Ang A.J.S., Wong L.W.J., Choo S.P., Tai D.W.-M., Lee J.J.X. |
---|---|
Other Authors: | DEAN'S OFFICE (DUKE-NUS MEDICAL SCHOOL) |
Format: | Article |
Published: |
S. Karger AG
2022
|
Subjects: | |
Online Access: | https://scholarbank.nus.edu.sg/handle/10635/214278 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application
by: Huo, Jin-Ling, et al.
Published: (2022) -
Targeting immune cells for cancer therapy
by: Gun, S.Y., et al.
Published: (2021) -
IMMUNOTHERAPY AGAINST ADVANCED CANCERS – CHIMERIC ANTIGEN RECEPTOR-BASED APPROACH AND IMMUNE CHECKPOINT REGULATION
by: TAY CHIN KANG JOHAN
Published: (2019) -
Predictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers
by: Sundar, R., et al.
Published: (2021) -
Cytokine Release Syndrome in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Case Series of 25 Patients and Review of the Literature
by: Tay, Sen Hee, et al.
Published: (2022)